Objective To evaluate the effect of inducing differenation of all trans retinoic acid (ATRA) on immunologic function of patients with gastric cancer. Methods T-lymphocyte subsets(T-Ls) and interleukin-2 receptor(sIL-2R) of 56 patients with gastric cancer after treatment of ATRA were studied. Results In radical gastric cancer resection group, the serum CD3,CD4 and CD4/CD8 rate were higher and sIL-2R were lower than those in the control group, after treatment of ATRA, CD3,CD4 and CD4/CD8 rate and sIL2R were as high as those in the control group. In the non-operative or palliative gastric resection group, CD3,CD4 and CD4/CD8 rates were increased markedly and the serum sIL-2R was decreased significantly than those in the control group. Conclusion ATRA inducing differenation can improve the immunity of the patients with gastric cancer.
To evaluate the role of octreotide in the treatment of severe acute pancreatitis (SAP). Seventy-six patients were divided into two groups (octreotide group, n＝38, control group, n＝38). All patients were treated by the same conservative regime. The octreotide group received octreotide. Results: The abdominal symptoms and signs, WBC count, serum amylase level, and volume of ascites were more effective controlled, with fewer complications occurred in octreotide group. Conclusion: Octreotide has a beneficial effect on the treatment of SAP, but the mechanism will be further investigated.
Objective To observe the efficacy of all trans retinoic acid (ATRA) combined with 5-Fu on treating subcutaneously implanted gastric carcinoma SGC 7901 in the nude mice. Methods Thirty-two nude mice bearing tumor were randomly divided into 4 groups: control group (group A), ATRA 1 000 μg/d orally taken group (group B), 5-Fu 27 mg/kg group peritoneally injected (group C), 5-Fu 13.5 mg/kg combined with ATRA 500 μg/d group (group D). Results Significant inhibition of tumor growth was shown in the group B, group C and group D as compared with group A (Ｐ＜0.01), with the tumor growth inhibition rate and the tumor weight inhibition rate at the 7 weeks after the treatment being 56.88%, 49.00%, 70.00% and 56.10%, 51.64%, 76.95%. Conclusion ATRA combined with 5-Fu can enhance the effects of 5-Fu in treating gastric carcinoma.